Why has UNVC never disclosed a signed, binding material contract or commercial licensing agreement with 11Three or its affiliates in official financial filings? Broad promotional statements about "joint commercialization pathways" or "e-prescribing network integrations" carry little legal weight without a confirmed, executed agreement disclosed in sworn corporate filings.
Why did 11Three quietly remove the flowcharts and references mapping their SENDS™ technology directly into Univec’s eDRLS, NDC listing, and DispenseDoc clinic billing pipeline? The Reality: Removing those specific diagrams eliminates the primary visual asset that tied 11Three’s formulation platform to UNVC's public stock narrative.
Why were the "Rx Only" product packaging mockups, executive bios, and academic advisor listings scrubbed from the partner site? The Reality: Promoting a product as a prescription-grade ("Rx Only"
asset while the physical product remains an unapproved wellness patch creates immediate regulatory liability. Deleting those mockups retroactively suggests an effort to mitigate exposure to FDA misbranding and SEC enforcement.
Selective Disclosure Concerns (Reg FD)
The Question: Why does UNVC designate its social media presence as "N/A" in official quarterly disclosures while actively using LinkedIn and press wires to broadcast material product updates? The Reality: Public companies cannot selectively broadcast speculative operational updates on social media to impact retail market sentiment while certifying to regulators that social channels are not used for material disclosures.
When the underlying supplier (11Three) scrubs all direct references to UNVC, NDC listings, and prescription infrastructure, it leaves the promotional claims made on social media without operational support. For shareholders, this pattern points to an attempt to generate market interest through unverified product claims rather than a fully executed, regulatory-compliant commercial launch.
People spending their money on false promotions deserve to know what is/has been going on for years with CEOs in the pink junk land.
PL
All these imagines have been scrubbed from 11three website;
Why did 11Three quietly remove the flowcharts and references mapping their SENDS™ technology directly into Univec’s eDRLS, NDC listing, and DispenseDoc clinic billing pipeline? The Reality: Removing those specific diagrams eliminates the primary visual asset that tied 11Three’s formulation platform to UNVC's public stock narrative.
Why were the "Rx Only" product packaging mockups, executive bios, and academic advisor listings scrubbed from the partner site? The Reality: Promoting a product as a prescription-grade ("Rx Only"
asset while the physical product remains an unapproved wellness patch creates immediate regulatory liability. Deleting those mockups retroactively suggests an effort to mitigate exposure to FDA misbranding and SEC enforcement. Selective Disclosure Concerns (Reg FD)
The Question: Why does UNVC designate its social media presence as "N/A" in official quarterly disclosures while actively using LinkedIn and press wires to broadcast material product updates? The Reality: Public companies cannot selectively broadcast speculative operational updates on social media to impact retail market sentiment while certifying to regulators that social channels are not used for material disclosures.
When the underlying supplier (11Three) scrubs all direct references to UNVC, NDC listings, and prescription infrastructure, it leaves the promotional claims made on social media without operational support. For shareholders, this pattern points to an attempt to generate market interest through unverified product claims rather than a fully executed, regulatory-compliant commercial launch.
People spending their money on false promotions deserve to know what is/has been going on for years with CEOs in the pink junk land.
PL
All these imagines have been scrubbed from 11three website;
1
